miR-483 is Down-Regulated in Polycystic Ovarian Syndrome and Inhibits KGN Cell Proliferation via Targeting Insulin-Like Growth Factor 1 (IGF1).
BACKGROUND Polycystic ovarian syndrome (PCOS) is a common metabolic disorder in premenopausal woman, characterized by hyperandrogenism, oligoanovulation, and insulin resistance. microRNAs play pivotal roles in regulating key factors of PCOS. However, relevant research remains limited. This study aimed to reveal the role and potential mechanism of miR-483 in PCOS. MATERIAL AND METHODS PCOS patients (n=20) were recruited for detecting miR-483 expression in lesion and normal ovary cortex. Human granulosa-like tumor cell line KGN was used to alter miR-483 expression by cell transfection. Cell viability and proliferation were analyzed by MTT assay and colony formation assay, and cell cycle was detected by flow cytometry. Interaction between miR-483 and IGF1 was verified by luciferase reporter assay. KGN cells were further treated by insulin to investigate the relationship between miR-483 and insulin. RESULTS miR-483 was significantly down-regulated in lesion ovary cortex from PCOS patients (P<0.001). In KGN cells, overexpression of miR-483 inhibited cell viability and proliferation, and induced cell cycle arrest. miR-483 also inhibited CCNB1, CCND1, and CDK2. miR-483 sponge induced the opposite effects. miR-483 directly targeted IGF1 3'UTR, and IGF1 promoted KGN cell proliferation and reversed miR-483-inhibited cell viability. Insulin treatment in KGN cells inhibited miR-483, and promoted IGF1 and cell proliferation. CONCLUSIONS These results suggest that miR-483 is a PCOS suppressor inhibiting cell proliferation, possibly via targeting IGF1, and that it is involved in insulin-induced cell proliferation. miR-483 is a potential alternative for diagnosing and treating PCOS.
Department of Reproductive Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Yungai
Y
Xiang
Department of Reproductive Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Yuxia
Y
Song
Department of Reproductive Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Yan
Y
Li
Department of Reproductive Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Dongmei
D
Zhao
Department of Reproductive Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Liying
L
Ma
Department of Reproductive Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Li
L
Tan
Int J Cell Biol. 2009;2009:243532
20414334
J Reprod Med. 2000 Oct;45(10):817-22
11077630
Endocr Rev. 2012 Dec;33(6):981-1030
23065822
J Endocrinol. 2006 Sep;190(3):739-47
17003275
Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007506
21328294
J Clin Endocrinol Metab. 2015 May;100(5):E729-38
25695884
Endocr Rev. 1995 Jun;16(3):322-53
7671850
PLoS Genet. 2010 Feb 26;6(2):e1000863
20195506
Diabetes. 2013 Jul;62(7):2278-86
23493574
J Endocrinol Invest. 2010 Apr;33(4):234-8
19820295
J Clin Endocrinol Metab. 1994 May;78(5):1052-8
8175959
Endokrynol Pol. 2011;62(2):120-8
21528473
FASEB J. 2011 Sep;25(9):3092-105
21676945
Eur J Endocrinol. 1998 Mar;138(3):269-74
9539300
J Clin Endocrinol Metab. 2004 Aug;89(8):3835-40
15292314
Reprod Biomed Online. 2015 Oct;31(4):565-72
26283014
Sci Rep. 2015 Nov 19;5:16890
26582398
Am J Cancer Res. 2014 Jan 15;4(1):73-9
24482740
J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5
10487660
Turk J Med Sci. 2014;44(5):781-6
25539545
Endocr Relat Cancer. 2013 Jan 07;20(1):R1-R17
23207292
J Clin Endocrinol Metab. 2004 Jun;89(6):2640-6
15181035
J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45
16940456
Int J Obes Relat Metab Disord. 2002 Jul;26(7):883-96
12080440
Clin Obstet Gynecol. 2007 Mar;50(1):168-77
17304034
Cell Cycle. 2013 Jul 15;12(14):2183-93
24067364
Dev Cell. 2014 Apr 28;29(2):217-32
24746669
Biol Reprod. 2002 Feb;66(2):297-304
11804942
Fertil Steril. 2005 Jun;83(6):1852-5
15950665
Cell Death Differ. 2013 Jun;20(6):800-11
23429262
Trends Endocrinol Metab. 2012 Oct;23(10):533-43
22939889
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1531-41
22761305
Mol Cell Endocrinol. 2013 Jul 5;373(1-2):51-60
22874072